Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline
Open accessThe DOI matches its Crossref record; 352 of the 356 references it cites were found in a registry or an index; none of the 390 sources its claims cite is checked for support yet.
Abstract
OBJECTIVE: The aim was to formulate practice guidelines for the diagnosis and treatment of polycystic ovary syndrome (PCOS). PARTICIPANTS: An Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer developed the guideline. EVIDENCE: This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence. CONSENSUS PROCESS: One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of The Endocrine Society and the European Society of Endocrinology reviewed and commented on preliminary drafts of these guidelines. Two systematic reviews were conducted to summarize supporting evidence. CONCLUSIONS: We suggest using the Rotterdam criteria for diagnosing PCOS (presence of two of the following criteria: androgen excess, ovulatory dysfunction, or polycystic ovaries). Establishing a diagnosis of PCOS is problematic in adolescents and menopausal women. Hyperandrogenism is central to the presentation in adolescents, whereas there is no consistent phenotype in postmenopausal women. Evaluation of women with PCOS should exclude alternate androgen-excess disorders and risk factors for endometrial cancer, mood disorders, obstructive sleep apnea, diabetes, and cardiovascular disease. Hormonal contraceptives are the first-line management for menstrual abnormalities and hirsutism/acne in PCOS. Clomiphene is currently the first-line therapy for infertility; metformin is beneficial for metabolic/glycemic abnormalities and for improving menstrual irregularities, but it has limited or no benefit in treating hirsutism, acne, or infertility. Hormonal contraceptives and metformin are the treatment options in adolescents with PCOS. The role of weight loss in improving PCOS status per se is uncertain, but lifestyle intervention is beneficial in overweight/obese patients for other health benefits. Thiazolidinediones have an unfavorable risk-benefit ratio overall, and statins require further study.
Overview
CoChat Summary
TL;DR
This Endocrine Society clinical practice guideline recommends using the Rotterdam criteria to diagnose PCOS in adults and emphasizes excluding mimics and assessing associated metabolic, cardiovascular, endometrial, mood, and sleep morbidity. It recommends hormonal contraceptives as first-line management for menstrual abnormalities and hirsutism/acne, clomiphene (or comparable estrogen modulators) as first-line therapy for anovulatory infertility, and metformin for T2DM/IGT or as second-line therapy for menstrual irregularity when hormonal contraceptives cannot be used.
Key findings
- PCOS diagnosis in adults should be made if two of three Rotterdam criteria are met—androgen excess, ovulatory dysfunction, or polycystic ovaries—after excluding thyroid disease, hyperprolactinemia, and nonclassic congenital adrenal hyperplasia; in adolescents, diagnosis should require clinical and/or biochemical hyperandrogenism plus persistent oligomenorrhea, because anovulatory symptoms and PCO morphology are not sufficient.
- Women with PCOS are at increased risk for impaired glucose tolerance and type 2 diabetes: the guideline states a 5- to 10-fold increased risk of developing T2DM, with overall glucose intolerance prevalence of 30–35% and T2DM in 3–10%; nonobese women with PCOS had 10–15% IGT and 1–2% T2DM.
- Hirsutism is present in approximately 65–75% of patients with PCOS, and PCOS represents the major cause of hirsutism; in a large study of patients with clinical hyperandrogenism, 72.1% of 950 patients were diagnosed with PCOS.
- Endometrial cancer risk is increased: a 31-year UK follow-up showed a 3.5 increased relative risk, and a meta-analysis reported RR = 2.7 (95% CI, 1.0–7.29), confirmed by a subsequent systematic review with a 3-fold increased risk.
- Depression and sleep-disordered breathing are also increased: one study reported major depression episode/recurrent depression OR 3.8 (95% CI, 1.5–8.7; P = .001) and suicide attempts seven times higher in PCOS cases vs controls; women with PCOS were 30 times more likely to have sleep-disordered breathing and nine times more likely to have daytime sleepiness after controlling for BMI.
Methods
- An Endocrine Society-appointed Task Force of experts, a methodologist, and a medical writer developed the guideline using the GRADE system to describe recommendation strength and evidence quality.
- Consensus was reached through one group meeting, several conference calls, and e-mail communications; committees and members of The Endocrine Society and the European Society of Endocrinology reviewed and commented on preliminary drafts.
- Two systematic reviews were conducted to summarize supporting evidence; recommendations use “we recommend” with number 1 for strong recommendations and “we suggest” with number 2 for weak recommendations, with cross-filled circles indicating evidence quality.
Limitations
- The guideline states that there are no adequately powered, randomized, double-blind, placebo-controlled trials in adolescents with PCOS; no large randomized trials of exercise in PCOS; and no long-term data assessing the effect of hormonal contraceptives on glucose tolerance in nondiabetic and diabetic women with PCOS.
- It states that there are currently no diagnostic criteria for PCOS in perimenopausal and menopausal women, no age-related testosterone cutoffs, and that testosterone assays used to diagnose hyperandrogenemia in women are imprecise.
- It notes that the Rotterdam ultrasound PCO criteria were not validated for adolescents, that there is a lack of well-defined cutoff points for androgen levels during normal pubertal maturation, and that many recommendations are weak because evidence is limited or inconclusive.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 201 Not checked · 50 Own results and interpretations
In the paper
“However, hirsutism was a major symptom in about 60% of adolescents in one study (27) and may be suggestive of PCOS in adolescents (28).”
§ Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 1.0 Diagnosis of PCOS
What the sources say
- Not checked yetcites [27] Pfeifer SM, Kives S Polycystic ovary syndrome in the adolescent. Obstet Gynecol Clin North Am. 2009; 36: 129– 152. 19344852
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
In the paper
“but our systematic review did not confirm this (211).”
§ Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 3.0 Treatment
What the sources say
- Not checked yetcites [211] Domecq JP, Prutsky G, Mullan R, et al Lifestyle modification programs in polycystic ovary syndrome: systematic review and meta-analysis [published online ahead of print October 3, 2013]. J Clin Endocrinol Metab. doi: 10.1210/jc.2013–2385. 24092832
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“although there were significant improvements in some metabolic parameters (mainly glycemic effects related to improvements in fasting blood glucose and insulin levels) (249, 250).”
§ Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 3.0 Treatment
What the sources say
- Not checked yetcites [249] Tang T, Glanville J, Orsi N, Barth JH, Balen AH The use of metformin for women with PCOS undergoing IVF treatment. Hum Reprod. 2006; 21: 1416– 1425. 16501038
- Not checked yetcites [250] Domecq JP, Prutsky G, Mullan R, et al Adverse effects of common treatments for polycystic ovary syndrome: a systematic review and meta-analysis [published online ahead of print October 3, 2013]. J Clin Endocrinol Metab. doi: 10.1210/jc.2013-2374. PMC5399491 24092830
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We found little evidence to support lifestyle change as an infertility treatment”
§ Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 3.0 Treatment
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
None of the sources cited for this claim have been checked yet.
In the paper
“Our own meta-analysis showed that weight loss had minimal effects on hirsutism and fertility”
§ Diagnosis and Treatment of Polycystic Ovary Syndrome: An Endocrine Society Clinical Practice Guideline > Method of Development of Evidence-Based Clinical Practice Guidelines > 3.0 Treatment
What the sources say
- Not checked yetcites [249] Tang T, Glanville J, Orsi N, Barth JH, Balen AH The use of metformin for women with PCOS undergoing IVF treatment. Hum Reprod. 2006; 21: 1416– 1425. 16501038
- Not checked yetcites [250] Domecq JP, Prutsky G, Mullan R, et al Adverse effects of common treatments for polycystic ovary syndrome: a systematic review and meta-analysis [published online ahead of print October 3, 2013]. J Clin Endocrinol Metab. doi: 10.1210/jc.2013-2374. PMC5399491 24092830
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
146 more claims
Create a free account to see all 252 claims and to verify the 390 references still open.
- It may state two separate claims as one. 78
- Probably not a substantial claim. 34
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Based on current guidelines, metformin is indicated in PCOS in some scenarios to improve fertility (Teede et al. , 2011; Legro et al. , 2013), for management of menstrual irregularity if women are unable to take OCPs, and in co-existent prediabetes or DM2, where lifestyle modification fails (Legro et al. , 2013).”
From Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis (2015) · cites this paper as Legro et al., 2013
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the interim there is inadequate evidence on the impact of metformin on glucose tolerance in prediabetes and DM2 specifically in PCOS, but based on data in general populations, current guidelines recommend using metformin in obese women with PCOS who have prediabetes or DM2 (Legro et al. , 2013).”
From Metformin and lifestyle modification in polycystic ovary syndrome: systematic review and meta-analysis (2015) · cites this paper as Legro et al. , 2013
Experimental — accuracy not yet measuredIn the citing paper
“It is indicated in combination with COCs, especially for overweight or obese patients, or when COCs are contraindicated [46].”
From Controversies in the Pathogenesis, Diagnosis and Treatment of PCOS: Focus on Insulin Resistance, Inflammation, and Hyperandrogenism (2022) · cites this paper as [46]
Citations
Cites
1 retracted
Shaw, L. J., Bairey Merz, C. N., Azziz, R., Stanczyk, F. Z., Sopko, G., Braunstein, G. D., Kelsey, S. F., Kip, K. E., Cooper-DeHoff, R. M., Johnson, B. D., et al. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0425 · Cited by 427
RetractedReduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Grading quality of evidence and strength of recommendations
(2004) · BMJ · doi:10.1136/bmj.328.7454.1490 · Cited by 8,477 · cited 1×
“implementation of evidence-based guidelines (4).”
The Rotterdam ESHRE/ASRM-sponsored PCOS consensus workshop group (2004) · Human Reproduction · doi:10.1093/humrep/deh098 · Cited by 6,138
The Diagnosis of Polycystic Ovary Syndrome during Adolescence
Witchel, S. F., Oberfield, S., Rosenfield, R. L., Codner, E., Bonny, A., Ibáñez, L., Pena, A., Horikawa, R., Gomez-Lobo, V., Joel, D., et al. (2015) · Hormone Research in Paediatrics · doi:10.1159/000375530 · Cited by 3,113
Self-citationThe diagnosis of Cushing's syndrome: an Endocrine Society Clinical Practice Guideline.
Nieman, L. K., Biller, B. M. K., Findling, J. W., Newell-Price, J., Savage, M. O., Stewart, P. M., & Montori, V. M. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0125 · Cited by 2,718 · cited 1×
“Cushing’s syndrome Many of the signs and symptoms of PCOS can overlap with Cushing’s (ie, striae, obesity, dorsocervical fat (ie, buffalo hump, glucose intolerance); however, Cushing’s is more likely to be present when a large number of signs and symptoms, especially those with high discriminatory index (eg, myopathy,…”
BackgroundThe Prevalence and Features of the Polycystic Ovary Syndrome in an Unselected Population
Azziz, R., Woods, K. S., Reyna, R., Key, T. J., Knochenhauer, E. S., & Yildiz, B. O. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-032046 · Cited by 2,712 · cited 1×
“Overall, hirsutism is present in approximately 65–75% of patients with PCOS (although lower in Asian populations) (15, 52).”
BackgroundPhysical Fitness and All-Cause Mortality: A Prospective Study of Healthy Men and Women
Blair, S. N. (1989) · JAMA · doi:10.1001/jama.1989.03430170057028 · Cited by 2,658 · cited 1×
“diovascular fitness, as measured by maximal oxygen consumption during exercise, is an independent predictor of cardiovascular mortality (229).”
BackgroundAzziz, R., Carmina, E., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Futterweit, W., Janssen, O. E., Legro, R. S., Norman, R. J., Taylor, A. E., et al. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0178 · Cited by 2,143 · cited 1×
“Similarly, androgen levels decline with age in women with and without PCOS (serum T declines 50% between the ages of 20 and 40 y) (43–45), with reports of improved menstrual frequency in PCOS (46, 47), although there is little evidence to support a decline in serum T associated with the menopause transition per se (43…”
BackgroundSelf-citation
Research works printed but not linked: 1
- [286]Tanner JM Growth and endocrinology of the adolescent. In: Gardner LI, ed. Endocrine and Genetic Diseases of Childhood and Adolescents. 2nd ed Philadelphia, PA: WB Saunders: 1975: 14.
Cited by
Items 701–800 of 1,004
Metabolic actions of insulin in ovarian granulosa cells were unaffected by hyperandrogenism
Zhao, S., Xu, H., Cui, Y., Wang, W., Qin, Y., Li, Y., Chan, W., Sun, Y. W., & Chen, Z. (2016) · Endocrine · doi:10.1007/s12020-016-0949-y · Cited by 22
MANAGEMENT OF ENDOCRINE DISEASE Hyperandrogenic states in women: pitfalls in laboratory diagnosis
PUGEAT, M. M., Plotton, I., de la Perrière, A. B., Raverot, G., Déchaud, H., & Raverot, V. (2018) · European Journal of Endocrinology · doi:10.1530/eje-17-0776 · Cited by 23
Cree‐Green, M., Cai, N. M., Thurston, J. E., Coe, G. V., Newnes, L., Garcia‐Reyes, Y., Baumgartner, A., Pyle, L. L., & Nadeau, K. J. (2018) · Pediatric Diabetes · doi:10.1111/pedi.12778 · Cited by 22
“Both guidelines were developed out of recognition that PCOS in adolescents may not be the same as in adult women, in part because of more severe IR secondary to pubertal changes.(1,6) Yet, despite recognition of unique metabolism of IR in adolescents and screening recommendations, IR is best measured by a hyperinsulin…”
BackgroundMethodInfluentialLiao, W., Su, C.-C., Lee, M.-T., Li, C.-J., Lin, C., Chiang, J., & Yen, H. (2019) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2019.112091 · Cited by 22
Meyer, M. L., Sotres‐Alvarez, D., Steiner, A. Z., Cousins, L. M., Talavera, G. A., Cai, J., Daviglus, M. L., & Loehr, L. R. (2020) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa012 · Cited by 22
“Irregular menstrual cycles are a phenotype of PCOS, a common cause of menstrual cycle disorders (26-28).”
BackgroundPolycystic Ovary Syndrome: A Brief Review with Recent Updates
Shermin, S., Noor, A., & Jahan, S. (2020) · Delta Medical College Journal · doi:10.3329/dmcj.v7i2.45567 · Cited by 23
The effect of clomiphene citrate on oxidative stress parameters in polycystic ovarian syndrome
Peker, N., Turan, G., Ege, S., Bademkıran, M. H., Karaçor, T., & Erel, Ö. (2020) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443615.2020.1719052 · Cited by 23
Oriolo, C., Fanelli, F., Castelli, S., Mezzullo, M., Altieri, P., Corzani, F., Pelusi, C., Repaci, A., Dalmazi, G. D., Vicennati, V., et al. (2020) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01235-3 · Cited by 22
Self-citationSerum β-Klotho concentrations are increased in women with polycystic ovary syndrome
Bednarska, S., Fryczak, J., & Siejka, A. (2020) · Cytokine · doi:10.1016/j.cyto.2020.155188 · Cited by 22
Kamrul-Hasan, A. B. M., Aalpona, F. T. Z., & Selim, S. (2020) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2020.16.2.156 · Cited by 22
“Patients were included if they had a diagnosis of PCOS meeting the revised Rotterdam criteria, 2003; the diagnosis of PCOS in adolescent girls was made based on the presence of clinical and/or biochemical evidence of hyperandrogenism (after exclusion of other pathologies) in the presence of persistent menstrual irregu…”
MethodO impacto da mudança do estilo de vida em mulheres com síndrome dos ovários policísticos
Campos, A. E., Leão, M. E. B., & Souza, M. A. D. (2021) · Revista Eletrônica Acervo Saúde · doi:10.25248/reas.e4354.2021 · Cited by 25
Yang, R. J., Gao, C., Yan, Y., Huang, Y., Wang, J., Zhang, C., Ma, X., Li, N., Du, X., Zhang, L., et al. (2021) · Sleep And Breathing · doi:10.1007/s11325-021-02376-2 · Cited by 22
Chatzakis, C., Tsakmaki, E., Psomiadou, A., Charitakis, N., Eleftheriades, M. I., Dinas, K. D., Goulis, D. G., & Sotiriadis, A. (2022) · Fertility and Sterility · doi:10.1016/j.fertnstert.2021.12.027 · Cited by 23
Polycystic ovary syndrome in adolescent girls
Baldauff, N. H., & Witchel, S. F. (2016) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000309 · Cited by 22
Sebastian, M. R., Wiemann, C. M., Bacha, F. F., & Taylor, S. A. (2018) · Journal of Pediatric and Adolescent Gynecology · doi:10.1016/j.jpag.2018.01.007 · Cited by 22
Prediabetes and diabetes in a cohort of Qatari women screened for polycystic ovary syndrome
Dargham, S. R., Elshewehy, A. M. M., Dakroury, Y., Kilpatrick, E. S., & Atkin, S. L. (2018) · Scientific Reports · doi:10.1038/s41598-018-21987-6 · Cited by 23
Almalki, H. H., Alshibani, T. M., Alhifany, A. A., & Almohammed, O. A. (2020) · BMC Women s Health · doi:10.1186/s12905-020-00919-5 · Cited by 22
Iwata, M. C., Porquere, L., Sorpreso, I. C. E., Baracat, E. C., & Soares, J. M. (2015) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.61.03.215 · Cited by 22
Role of obstructive sleep apnea in metabolic risk in PCOS
Sam, S., & Tasali, E. (2021) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2021.01.002 · Cited by 21
Bai, T., Deng, X., Bi, J., Ni, L., Li, Z., & Zhuo, X. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1471243 · Cited by 21
Palomba, S., Seminara, G., Costanzi, F., Caserta, D., & Aversa, A. (2024) · Biomedicines · doi:10.3390/biomedicines12122859 · Cited by 21
Barraza-Ortega, E., Gómez‐Gil, B., García-Gasca, T., Lizárraga, D., Díaz, N., & García-Gasca, A. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26178574 · Cited by 21
“Treatment options may include lifestyle changes and the use of insulin sensitisers, such as metformin, which have shown both metabolic and reproductive benefits [77].”
Serum Copper Level and Polycystic Ovarian Syndrome: A Meta-Analysis
Jiang, Q., Zhang, F., Han, L., Zhu, B., & Liu, X. (2021) · Gynecologic and Obstetric Investigation · doi:10.1159/000516518 · Cited by 21
Sumathi, M., Chitra, P., Sheela, S., & Ishwarya, C. (2023) · The Imaging Science Journal · doi:10.1080/13682199.2023.2229016 · Cited by 21
“A working party of the European Society of Human Reproduction and Embryology (ESHRE) has stressed the importance of being vigilant for the long-term health of women with PCOS [2 – 4].”
PCOS health-related quality-of-life and depressive symptoms across the lifespan: Comparative study
Wright, P. J., Tavakoli, A. S., & Corbett, C. F. (2023) · Journal of Women & Aging · doi:10.1080/08952841.2023.2230112 · Cited by 22
“Of women diagnosed with PCOS, approximately 50% have obesity, 70% have dyslipidemia, and 80% have insulin resistance (Legro et al., 2013).”
BackgroundExploring the Predictive Role of 11‐Oxyandrogens in Diagnosing Polycystic Ovary Syndrome
Mody, A., Lodish, M. B., Auchus, R. J., Turcu, A. F., Jiang, F., & Huddleston, H. G. (2025) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.70022 · Cited by 21
Targets to treat androgen excess in polycystic ovary syndrome
Luque‐Ramírez, M., & Escobar-Morreale, H. F. (2015) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2015.1075511 · Cited by 21
“However, clinical guidelines do not recommend GCs for the routine treatment of hirsutism in women with PCOS due to their limited efficacy compared with OCPs and antiandrogens, and their potential side effects [40-42].”
BackgroundCurrent Therapies for the Medical Management of Diabetes
Inzucchi, S. E., & Majumdar, S. K. (2016) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000001332 · Cited by 22
“In polycystic ovary syndrome, metformin can be used as a second-line therapy for diabetes prevention in those unable to achieve lifestyle modification and in those who seek to normalize menses but are unable to tolerate oral contraceptives.(28) The major limitations of metformin are gastrointestinal side effects, conc…”
BackgroundGourgari, E., Lodish, M. B., Keil, M. F., Sinaii, N., Turkbey, E. B., Lyssikatos, C., Nesterova, M., Sierra, M. D. L. L., Xekouki, P., Khurana, D., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-4019 · Cited by 21
Li, J., Ng, E. H. Y., Stener‐Victorin, E., Hu, Z., Shao, X., Wang, H., Li, M., Lai, M., Xie, C., Su, N., et al. (2017) · Trials · doi:10.1186/s13063-017-1854-2 · Cited by 21
“Nevertheless, it is not effective in treating hirsutism, acne, or anovulatory infertility [12].”
BackgroundCarolo, A. L., Mendes, M. C., Silva, A. C. J. D. S. R. E., Vieira, C. S., de Sá, M. F. S., Ferriani, R. A., & dos Reis, R. M. (2017) · Revista Brasileira Ginecologia e Obstetrícia · doi:10.1055/s-0037-1607458 · Cited by 21
Does Metformin Treatment During Pregnancy Modify the Future Metabolic Profile in Women With PCOS?
Underdal, M. O., Stridsklev, S., Oppen, I. H., Høgetveit, K., Andersen, M., & Vanky, E. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00485 · Cited by 21
Goyal, A., & Ganie, M. A. (2018) · Cureus · doi:10.7759/cureus.3004 · Cited by 21
Merhi, Z. O. (2018) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2018.08.010 · Cited by 21
Dennd1a, a susceptibility gene for polycystic ovary syndrome, is essential for mouse embryogenesis
Shi, J., Gao, Q., Cao, Y., & Fu, J. (2019) · Developmental Dynamics · doi:10.1002/dvdy.28 · Cited by 21
“The diagnosis of this disorder includes hyperandrogenemia, chronic anovulation and/or polycystic ovaries.(8,9) The PCOS is thought to be caused by a combination of genetic and environmental factors.”
BackgroundShahrokhi, S. A., & Naeini, A. A. (2019) · Journal of Obstetrics and Gynaecology · doi:10.1080/01443615.2019.1603215 · Cited by 21
“…Amir Mansour Alavi am.alavi@nutr.mui.ac.ir Department of Community Nutrition, Isfahan University of Medical Science, 009831 Isfahan, Iran 2019 Informa UK Limited, trading as Taylor & Francis Group PCOS prognosis (Legro et al. 2013; Tsai et al. 2013; Sirmans and Pate 2014; Ressler et al. 2015).”
BackgroundActualización del manejo de síndrome de ovario poliquístico
Gaitán, E. S. (2019) · Revista Medica Sinergia · doi:10.31434/rms.v4i12.322 · Cited by 21
Copp, T., Cvejic, E., McCaffery, K. J., Hersch, J. K., Doust, J. A., Mol, B. W., Dokras, A., Mishra, G. D., & Jansen, J. (2020) · Human Reproduction · doi:10.1093/humrep/dez274 · Cited by 21
Current treatment for polycystic ovary syndrome: focus on adolescence
Street, M. E., Cirillo, F., Catellani, C., Dauriz, M., Lazzeroni, P., Sartori, C., & Moghetti, P. (2020) · Minerva Pediatrics · doi:10.23736/s0026-4946.20.05861-2 · Cited by 21
Zhang, W., Zuo, M., Lu, J., & Wang, Y. (2020) · Reproductive Sciences · doi:10.1007/s43032-020-00237-z · Cited by 21
Steiner, N., Ates, S., Shaulov, T., Shrem, G., Volodarsky‐Perel, A., Dahan, S., Tannus, S., Son, W.-Y., & Dahan, M. H. (2020) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-020-05699-9 · Cited by 21
Andrisse, S., Garcia‐Reyes, Y., Pyle, L. L., Kelsey, M. M., Nadeau, K. J., & Cree‐Green, M. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab008 · Cited by 21
Liu, S., Hong, L., Lian, R., Xiao, S., Li, Y., Diao, L., & Zeng, Y. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.874487 · Cited by 21
“The diagnosis of PCOS is mainly based on two of the three main features: oligo- or anovulation, hyperandrogenism (clinical or biochemical), and polycystic ovarian morphology (PCOM) on ultrasound, after exclusion of other causes (Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group, 2012; Legro et al., 2013…”
MethodHarris, R. A., Archer, K. J., Goodarzi, M. O., York, T. P., Rogers, J., Dunaif, A. E., McAllister, J. M., & Strauss, J. F. (2022) · Gene · doi:10.1016/j.gene.2022.147062 · Cited by 21
Yang, Q., & Wang, F. (2016) · Gynecologic and Obstetric Investigation · doi:10.1159/000446951 · Cited by 21
Antić, I. B., Ilic, D. S., Bjekić-Macut, J., Bogavac, T., Milutinović, D. V., Kastratović-Kotlica, B., Milic, N. M., Stanojlović, O. P., Andric, Z. G., & Μacut, D. (2016) · European Journal of Endocrinology · doi:10.1530/eje-16-0775 · Cited by 21
Polycystic ovary syndrome, body mass index and hypertensive disorders in pregnancy
Lønnebotn, M., Natvig, G. K., Benediktsdóttir, B., Burgess, J. A., Holm, M., Jögi, R., Lindberg, E., Macsali, F., Schlünssen, V., Skulstad, S. M., et al. (2017) · Pregnancy Hypertension · doi:10.1016/j.preghy.2017.12.006 · Cited by 21
Chronotype: A Tool to Screen Eating Habits in Polycystic Ovary Syndrome?
Barrea, L., Verde, L., Vetrani, C., Savastano, S., Colao, A., & Muscogiuri, G. (2022) · Nutrients · doi:10.3390/nu14050955 · Cited by 20
“Criteria for exclusion from the study were: age <18 and ≥40 years; menopause (defined as amenorrhea for ≥3 years or amenorrhea for ≥1 but <3 years and plasma folliclestimulating hormone concentrations elevated into the postmenopausal range); pregnancy or lactation in the last 6 months (15 women); not ovary-related hyp…”
BackgroundIs cardiorespiratory fitness impaired in PCOS women? A review of the literature
Donà, S., Bacchi, E., & Moghetti, P. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-016-0599-1 · Cited by 20
Garin, M. C., Butts, S. F., Sarwer, D. B., Allison, K. C., Senapati, S., & Dokras, A. (2016) · Endocrine · doi:10.1007/s12020-016-1210-4 · Cited by 20
Yang, M., Bai, W., Jiang, B., Wang, Z., Wang, X.-X., Sun, Y., Liu, F., Cui, G., Song, X., Li, J., et al. (2022) · Reproductive BioMedicine Online · doi:10.1016/j.rbmo.2022.03.023 · Cited by 20
Construction of a ceRNA network in polycystic ovary syndrome (PCOS) driven by exosomal lncRNA
Bai, L., Gong, J., Guo, Y., Li, Y., Huang, H., & Liu, X. (2022) · Frontiers in Genetics · doi:10.3389/fgene.2022.979924 · Cited by 20
“The most widely used classification of PCOS is the Rotterdam definition, which is currently supported by most scientific and health sectors (Legro et al., 2013).”
MethodZhang, Q., Wang, Z., Ding, J., Yan, S., Hao, Y., Chen, H., Yang, J., & Hu, K. (2023) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.10780 · Cited by 20
Mahmoud, M. M., Rashed, L. A., Soliman, S. A. M., Sayed, S. M., Kamel, O., Kamar, S. S., & Hussien, R. E. S. (2023) · Physiological Reports · doi:10.14814/phy2.15858 · Cited by 20
“Accordingly, management of PCOS should not aim only to improve the symptoms, it should address both the reproductive and metabolic diseases associated with PCOS (Legro et al., 2013; Teede et al., 2018).”
BackgroundLi, L., Feng, Q., Xiao, Y., Zhou, J., Hu, K., Li, X., Peng, X., Li, J., Li, Y., Zhong, M., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24338 · Cited by 20
Bo, Y., Zhao, J., Liu, C., & Yu, T. (2025) · BMC Women s Health · doi:10.1186/s12905-025-03594-6 · Cited by 20
National consensus on the management of patients with hyperandrogenism (2016)
Володимирович, К. В., Татарчук, Т. Ф., & Dubossarska, Y. O. (2016) · Reproductive Endocrinology · doi:10.18370/2309-4117.2016.30.19-31 · Cited by 20
Gynecologic and reproductive health in patients with pathogenic germline variants in DICER1
Merideth, M. A., Harney, L. A., Vyas, N. M., Bachi, A., Carr, A. G., Hill, D. A., Dehner, L. P., Schultz, K. A. P., Stewart, D. R., & Stratton, P. (2020) · Gynecologic Oncology · doi:10.1016/j.ygyno.2019.12.037 · Cited by 20
“Four of these nine women had prior diagnosis of polycystic ovarian disease (PCOS) based on standard criteria(19).”
BackgroundSaslow, L. R., & Aikens, J. E. (2020) · JMIR Formative Research · doi:10.2196/17126 · Cited by 20
Price, S., Sumithran, P., Prendergast, L. A., Nankervis, A. J., Permezel, M., & Proietto, J. (2020) · Fertility and Sterility · doi:10.1016/j.fertnstert.2020.06.033 · Cited by 20
Síndrome de ovario poliquístico
Winnykamien, I., Dalibón, A., & Knoblovits, P. (2017) · Revista del Hospital Italiano de Buenos Aires · doi:10.51987/rev.hosp.ital.b.aires.v37i1.842 · Cited by 20
Relationship between sleep disorders and female infertility among US reproductive-aged women
Zhao, J., Chen, Q., & Xue, X. (2023) · Sleep And Breathing · doi:10.1007/s11325-023-02802-7 · Cited by 20
“One clinical practice guideline on PCOS stated that when evaluating women with PCOS, obstructive sleep apnea (OSA) should be excluded [54].”
BackgroundChun, S. (2015) · Gynecological Endocrinology · doi:10.3109/09513590.2015.1056143 · Cited by 20
Pazderska, A., Tun, T. K., Phelan, N., McGowan, A. N., Sherlock, M., Behan, L., Boran, G. P., & Gibney, J. (2018) · Clinical Endocrinology · doi:10.1111/cen.13542 · Cited by 20
Ulrich, J., Goerges, J., Keck, C., Müller‐Wieland, D., Diederich, S., & Janssen, O. E. (2018) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0043-110480 · Cited by 20
Financial Conflicts of Interest Among Authors of Endocrine Society Clinical Practice Guidelines*
Irwig, M. S., Kyinn, M., & Shefa, M. C. (2018) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-00526 · Cited by 20
Metabolic syndrome in children (Review)
Wu, Y., Zhang, C.-L., & Zhen, Q. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3632 · Cited by 20
Palomba, S., & Sala, G. B. L. (2015) · Human Reproduction · doi:10.1093/humrep/dev284 · Cited by 20
Wright, P. J., Corbett, C. F., Pinto, B. M., Dawson, R. M., & Wirth, M. D. (2021) · Women s Health · doi:10.1177/17455065211065865 · Cited by 19
Female pattern hair loss and polycystic ovarian syndrome: more than just hirsutism
Jiang, V. S., Hawkins, S. D., & McMichael, A. J. (2022) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000777 · Cited by 19
“Although diagnostic criteria vary depending on definition, the 2003 Rotterdam criteria currently serves as the most clinically relevant and widely used diagnostic criteria within theUnited States as supported by ASRM, ESHRE, and the Endocrine Society [5].”
MethodMetformin is associated with reduced COVID-19 severity in patients with prediabetes
Chan, L., Casiraghi, E., Laraway, B. J., Coleman, B., Blau, H., Zaman, A., Harris, N. L., Wilkins, K. J., Antony, B., Gargano, M. A., et al. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.110157 · Cited by 19
“There are no medications approved by the Food and Drug Administration (FDA) for treating PCOS; available therapies are largely used to manage symptoms [25].”
BackgroundThe Role of Peroxisome Proliferator-Activated Receptors in Polycystic Ovary Syndrome
Psilopatis, I., Vrettou, K., Nousiopoulou, E., Palamaris, K., & Theocharis, S. E. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12082912 · Cited by 20
“Given that women with PCOS are at high risk of serious comorbidities, metabolic screening, and monitoring, alongside the evaluation of mental health and quality of life, should take place both at the first visit and at regular time intervals [5].”
BackgroundChen, H., Zeng, R., Zeng, X., & Qin, L. (2023) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002787 · Cited by 19
“[8] Recently, elevated serum anti-Müllerian hormone (AMH) levels have been recognized as a substitute for PCOM for its strong association with the number of follicles.”
BackgroundMukherjee, P., Sanyal, S., Chadha, S., & Mukherjee, S. (2023) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/0118715303266512231103075551 · Cited by 19
Ruan, L., Lv, X.-Y., Hu, Y., Chen, M., Jing-Tang, Zhong, Z.-H., Bao, M., Fu, L., Luo, X., Yu, S.-M., et al. (2024) · Journal of Ovarian Research · doi:10.1186/s13048-024-01411-6 · Cited by 19
“These diagnostic criteria are derived from the Rotterdam criteria [20].”
MethodMachado, M. F., Shunk, T., Hansen, G., Harvey, C., Fulford, B., Hauf, S., Schuh, O., Kaldas, M., Arcaroli, E., Ortiz, J. P., et al. (2024) · Cureus · doi:10.7759/cureus.66691 · Cited by 19
“Although the first-line interventions involve lifestyle measures [6,15] to promote weight loss and improve insulin resistance, the development and clinical use of targetable pharmacological interventions has become of interest to attain optimal therapeutic results, especially for women with obesity…”
BackgroundMethodPalomba, S., Seminara, G., Tomei, F., Marino, A. A., Morgante, G., Baldini, D., Papaleo, E., Ragusa, G., Aversa, A., Allegra, A., et al. (2025) · Reproductive Biology and Endocrinology · doi:10.1186/s12958-025-01372-5 · Cited by 20
Suvarna, Y., Maity, N., Kalra, P., & Shivamurthy, M. (2016) · Journal of the Turkish-German Gynecological Association · doi:10.5152/jtgga.2016.16129 · Cited by 19
Can AMH levels predict the need for increased medication during IVF/ICSI in PCOS women?
Kamel, A., Ramadan, W., Hussein, A. M., Dahab, S., Elsherbini, M. M., Lasheen, Y. S., & Abuhamila, F. A. (2016) · The Journal of Maternal-Fetal & Neonatal Medicine · doi:10.1080/14767058.2016.1272567 · Cited by 19
Long, J., Li, L., Wang, F., Yang, G., Cheng, W., Wei, J., Chen, M., & Liu, D. (2019) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2019.0019 · Cited by 19
Ramachandran, S., Nikitha, J., Gopi, C., Amala, M., & Dhanaraju, M. D. (2020) · Journal of Taibah University Medical Sciences · doi:10.1016/j.jtumed.2020.02.002 · Cited by 19
Diagnosis and Treatment of Polycystic Ovary Syndrome in Adolescent Females
Ebersole, A. M., & Bonny, A. E. (2020) · Clinical Obstetrics & Gynecology · doi:10.1097/grf.0000000000000538 · Cited by 19
Agrawal, K., Mathur, R., Purwar, N., Mathur, S. K., & Mathur, D. K. (2021) · Dermatology · doi:10.1159/000512918 · Cited by 19
Clinical, Metabolic and Hormonal Profiles of Bangladeshi Adolescents with Polycystic Ovary Syndrome
Kamrul-Hasan, A. B. M., Aalpona, F. T. Z., & Selim, S. (2021) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2021.17.1.54 · Cited by 19
Abdollahi, S., Meshkini, F., Clark, C. C. T., Heshmati, J., & Soltani, S. (2021) · British Journal Of Nutrition · doi:10.1017/s0007114521003780 · Cited by 19
“included studied population, is known to improve lipid profile(78), liver function(79) and ovarian function(80), beyond glycaemic control.”
BackgroundDiagnosis and treatment of polycystic ovary syndrome (PCOS): An interview with Richard Legro
Legro, R. S. (2015) · BMC Medicine · doi:10.1186/s12916-015-0299-2 · Cited by 19
“See references [1-10].”
Self-citationMetformin in women with PCOS, CONS
Misso, M. L., & Teede, H. J. (2014) · Endocrine · doi:10.1007/s12020-014-0394-8 · Cited by 19
Comparison of Finasteride, Metformin, and Finasteride Plus Metformin in PCOS
Diri, H., Bayram, F., Simsek, Y., Caliskan, Z., & Kocer, D. (2017) · Acta Endocrinologica (Bucharest) · doi:10.4183/aeb.2017.84 · Cited by 19
“Although metformin has been reported to have limited clinical effectiveness and is inferior to anti-androgen drugs in treating hirsutism, androgenic alopecia, and acne in patients with PCOS (21, 29), studies have clearly shown that metformin has significant beneficial effects on those features of PCOS (12, 30, 31).”
BackgroundThe incidence of metabolic syndrome in adolescents with different phenotypes of PCOS
Altıntaş, K., Dilbaz, B., Cırık, D. A., Özelçi, R., Zengin, T., Erginay, O. N., & Dilbaz, S. (2017) · Ginekologia Polska · doi:10.5603/gp.a2017.0055 · Cited by 19
Increased serum neuregulin 4 levels in women with polycystic ovary syndrome: A case-control study
Temür, M., Çalan, M., Akşit, M., Yılmaz, Ö., Çift, T., Akselim, B., Çakmak, B. D., & Üstünyurt, E. (2017) · Ginekologia Polska · doi:10.5603/gp.a2017.0095 · Cited by 19
Mental health and body image in polycystic ovary syndrome.
Lee, I., & Dokras, A. (2020) · Current Opinion in Endocrine and Metabolic Research · doi:10.1016/j.coemr.2020.04.004 · Cited by 18
A Narrative Review of Quercetin’s Role as a Bioactive Compound in Female Reproductive Disorders
Khamineh, Y., Ghiasvand, M., Panahi-Alanagh, S., Rastegarmand, P., Zolghadri, S., & Stanek, A. (2025) · Nutrients · doi:10.3390/nu17071118 · Cited by 18
“It is important to note that obese women with PCOS may experience reduced effectiveness and lower pregnancy rates when using these medications to induce ovulation [51].”
Beneficial Effects of Probiotics on Benign Gynaecological Disorders: A Review
Norfuad, F. A., Mokhtar, M. H., & Ghani, N. A. A. (2023) · Nutrients · doi:10.3390/nu15122733 · Cited by 18
Zeng, H., Zhang, Y., Huang, S., Wu, J., Ren, W., Zhou, L., Huang, L., & Ye, Y. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1223768 · Cited by 19
Wang, G., Liu, X., Zhu, S., & Lei, J. (2024) · Journal of Advanced Nursing · doi:10.1111/jan.16220 · Cited by 18
Livadas, S., Bothou, C., Kanaka‐Gantenbein, C., Chiotis, D., Angelopoulos, N., Μacut, D., & Chrousos, G. P. (2020) · Hormone and Metabolic Research · doi:10.1055/a-1109-2630 · Cited by 18
“However, it should be noted that oligo-amenorrhea is strongly associated with chronic oligo-anovulation [33].”
Backgroundde Medeiros, S. F., de Medeiros, M. A. S., Barbosa, B. B., Yamamoto, M. M. W., & Maciel, G. A. R. (2020) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-020-05867-x · Cited by 18
Jahromi, B. N., Borzou, N., Parsanezhad, M. E., Anvar, Z., Ghaemmaghami, P., & Sabetian, S. (2021) · International Journal of Reproductive BioMedicine (IJRM) · doi:10.18502/ijrm.v19i7.9476 · Cited by 18
“Modifications of lifestyle and diet according to the medical guidelines and preventive strategies in general practice is the first line of treatment for PCOS (6).”
BackgroundCarmina, E. (2022) · Diagnostics · doi:10.3390/diagnostics12102555 · Cited by 18
Nagpal, N., Messito, M. J., Katzow, M. W., & Gross, R. S. (2022) · Pediatrics in Review · doi:10.1542/pir.2021-005095 · Cited by 18
Metadata
- Authors
- Legro, R. S., Arslanian, S. A., Ehrmann, D. A., Hoeger, K. M., Murad, M. H., Pasquali, R., & Welt, C. K.
- Affiliations
- Pennsylvania State University (US)
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2013-12
- Volume
- 98
- Issue
- 12
- Pages
- 4565-4592
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- PMC
- PMC5399492
- OpenAlex
- W2120973019
- Cited by
- 1,919
- References
- 356
- Citations by year
- 2026: 104 · 2025: 135 · 2024: 149 · 2023: 181 · 2022: 207 · 2021: 197 · 2020: 149 · 2019: 160 · 2018: 145 · 2017: 129 · 2016: 131 · 2015: 124 · 2014: 95 · 2013: 6
- FWCI
- 143.77
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion)
- Funders
- European Society of Endocrinology
- National Institute of Diabetes and Digestive and Kidney Diseases (P60DK020595, P30DK020595)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD065029)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
- Keywords
- polycystic ovary syndrome, PCOS diagnosis, Rotterdam criteria, hyperandrogenism, ovulatory dysfunction, PCOS treatment, hormonal contraception, clomiphene citrate, metformin, insulin resistance, menstrual irregularity, hirsutism, acne, infertility, adolescents, menopausal women, weight loss, lifestyle intervention, thiazolidinediones, statins, cardiovascular risk
- MeSH terms
- Adolescent, Adult, Age Factors, Female, Humans, Middle Aged, Polycystic Ovary Syndrome, Societies, Scientific, Evidence-Based Medicine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.